18F-DCFPyL PET定量阈值判断前列腺癌恶性:病理对照研究
该多中心回顾性研究纳入305例前列腺癌患者的476个PET感兴趣区,与组织病理匹配,评估18F-DCFPyL PSMA PET定量参数鉴别恶性与良性组织的能力。结果显示SUVmax与血池比值判别性能最佳,阈值2.86–2.97,敏感度0.841–0.950,特异度0.788–0.911;前列腺病灶SUVmax阈值5.43时敏感度0.843、特异度0.927。
要点
- SUVmax/血池比值在全部、前列腺及转移灶中判别性能最高,阈值2.86–2.97。
- 前列腺病灶SUVmax阈值5.43,敏感度0.843,特异度0.927。
- TLU/血池、肝、脾比值也表现良好,联合临床变量可进一步提升判别。
核心结论
- SUVmax与血池比值及TLU与血池比值可区分前列腺癌恶性与良性组织,可能辅助活检选择等临床决策。
研究设计与样本
- 多中心回顾性研究,纳入4家机构305例前列腺癌患者,共476个PET感兴趣区与组织病理匹配。
主要发现
- 全部病灶中除TV外所有PSMA PET参数与恶性相关(TV P=0.011,其他P<0.001)。
- 转移灶中除TV外所有参数与恶性相关(TV P=0.001,其他P<0.001)。
- 前列腺病灶中除TV外所有参数与恶性相关(TV P=0.970,其他P<0.001)。
- SUVmax/血池比值在全部、前列腺及转移灶中判别性能最高,阈值2.86–2.97,敏感度0.841–0.950,特异度0.788–0.911。
- 前列腺病灶SUVmax阈值5.43,敏感度0.843,特异度0.927。
关键数值与推荐
- SUVmax/血池比值阈值2.86–2.97,敏感度0.841–0.950,特异度0.788–0.911。
- 前列腺病灶SUVmax阈值5.43,敏感度0.843,特异度0.927。
- TLU/血池、肝、脾比值也表现良好。
- PET参数联合临床变量的多变量模型可进一步改善恶性与良性病变的判别。
临床怎么用
- 可利用SUVmax/血池比值及TLU/血池比值等定量阈值辅助鉴别前列腺癌恶性与良性组织。
- 前列腺病灶SUVmax阈值5.43可作为活检选择的参考依据之一。
局限性
- 需要更大规模研究进一步确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this article, we assess histologically validated quantitative parameters on 18F-piflufolastat (18F-DCFPyL) prostate-specific membrane antigen (PSMA) PET and identify thresholds for differentiating malignant prostate cancer from benign tissue. Methods: In this multicenter retrospective study, men with prostate cancer who underwent 18F-DCFPyL PET/CT followed by surgery or biopsy at 4 institutions were included. Histopathology reports and CT-guided biopsy images were anatomically matched to PET/CT, and corresponding regions of interest were delineated. Univariable associations between lesion malignancy and PET parameters (SUVmax/mean, total lesion uptake (TLU), tumor volume (TV), ratios to blood, liver, and spleen) were tested using likelihood ratio tests. Multivariable models incorporating PET and clinical variables were also evaluated. Analyses were performed for all lesions combined and separately for prostate and metastatic lesions. Results: In total, 305 men with 476 PET regions of interest matched to histologic specimens were analyzed. Across all lesions, malignancy was associated with all PSMA PET parameters (P = 0.011 for TV; P < 0.001 for all other metrics). Similar associations were observed in metastatic lesions (P = 0.001 for TV; P < 0.001 for all other metrics). In prostate lesions, malignancy was associated with all PET parameters except TV (P = 0.970 for TV; P < 0.001 for all other metrics). Among all evaluated metrics, SUVmax to blood-pool ratio showed the highest discriminatory performance across all lesions, prostate lesions, and metastatic lesions, with thresholds ranging from 2.86 to 2.97, sensitivities from 0.841 to 0.950, and specificities from 0.788 to 0.911. Ratios of TLU to blood-pool, liver, and spleen also performed well. SUVmax, SUVmean, and TLU yielded good sensitivity across cohorts, although specificity was lower in some subgroups. For prostate lesions, the SUVmax threshold of 5.43 yielded a sensitivity of 0.843 and a specificity of 0.927. Multivariable models combining PET parameters, particularly blood-pool and liver-referenced metrics, with clinical variables further improved discrimination between malignant and benign lesions. Conclusion: SUVmax-to-blood and TLU-to-blood cutoffs can distinguish malignant prostate cancer from benign tissue and may support clinical decision-making, including biopsy selection. Larger studies are required for further confirmation.
引用
- Lindenberg L, Huang E, Ulaner GA, et al. Quantitative Thresholds on 18F-DCFPyL PET for Determining Malignancy in Prostate Cancer with Pathologic Correlation. J Nucl Med. 2026. PMID: 42722438. doi:10.2967/jnumed.126.272271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。